Linatilsan (Enalapril Maleate)

Enalapril is converted in the body to enalaprilat, which blocks the angiotensin‑converting enzyme (ACE). This inhibition prevents the formation of angiotensin II, a potent vasoconstrictor, and reduces aldosterone release, leading to vasodilation, lower blood pressure, and decreased fluid retention.

The appropriate dose of Linatilsan is determined by a qualified healthcare professional based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the prescribing physician’s instructions and not adjust the dose on their own.

Safety of enalapril during pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a healthcare provider.

To order Linatilsan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linatilsan (enalapril) is comparable to other ACE inhibitors such as lisinopril or ramipril in efficacy for blood‑pressure control and heart‑failure management. Unlike ARBs, which block angiotensin II receptors, ACE inhibitors also increase bradykinin levels, which can lead to a characteristic dry cough in some patients.

Linatilsan tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Linatilsan is taken orally, usually with or without food, as directed by a physician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious adverse reactions include angioedema (swelling of the face, lips, tongue or throat), severe hypotension, hyperkalemia (high potassium levels), and renal impairment. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden dizziness, or a rapid rise in blood potassium.

Linatilsan should be avoided in individuals with a known hypersensitivity to enalapril or any ACE inhibitor, those with a history of angioedema related to ACE‑inhibitor therapy, and patients with severe renal artery stenosis. Caution is also advised for patients with advanced kidney disease or high potassium levels.